In the News January 9, 2020

The Pink Sheet | Data Integrity ‘More than Just a GMP Issue’ As Attention to Clinical, Nonclinical Lapses Grows

Cathy Burgess comments on U.S. Food and Drug Administration requirements for the timely reporting of pharmaceutical data integrity concerns in preclinical and clinical research.
Media Contact
Alex Wolfe
Communications Director

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.